Cargando…

Incidence, mortality, and survival analyses of patients with thymic lymphoma

OBJECTIVES: To explore the clinical and prognostic characteristics of thymic lymphoma and the effects of current treatments on the prognosis. METHODS: Patients diagnosed as primary thymic lymphoma between 1975 and 2018 from the nine states of the US were identified, including Atlanta, Connecticut, D...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Li, Wang, Zhile, Huo, Lanqing, Zhao, Ailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516097/
https://www.ncbi.nlm.nih.gov/pubmed/36185268
http://dx.doi.org/10.3389/fonc.2022.933672
_version_ 1784798635224989696
author Wang, Li
Wang, Zhile
Huo, Lanqing
Zhao, Ailin
author_facet Wang, Li
Wang, Zhile
Huo, Lanqing
Zhao, Ailin
author_sort Wang, Li
collection PubMed
description OBJECTIVES: To explore the clinical and prognostic characteristics of thymic lymphoma and the effects of current treatments on the prognosis. METHODS: Patients diagnosed as primary thymic lymphoma between 1975 and 2018 from the nine states of the US were identified, including Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle–Puget Sound, and Utah. Incidence and mortality rates were analyzed using SEER*Stat 8.3.9 software. Univariate and multivariate Cox regressions were performed to identify prognostic factors. The Kaplan–Meier curve and log-rank test were used to compare overall survival (OS) among different treatments. RESULTS: A total of 233 patients diagnosed as thymic lymphoma were identified, and eight of them were lost to follow-up or died upon diagnosis. The incidence of thymic lymphoma was 2.032 per ten million (95% CI: 1.777–2.312), and the mortality rate was 0.649 per ten million (95% CI: 0.508–0.817). Among the 225 patients with definite follow-up, 98 were males and 127 were females, with a median age of 33 years. The Cox regression results showed that age and pathological type were independent risk prognostic factors. The 5-, 10-, and 20-year OS were 80.0%, 77.5%, and 70.9%, respectively. For Ann Arbor stage I and II patients, there was no significant difference between the surgical group (N = 78) and the non-operative group (N = 65; P = 0.270). The radiotherapy group (N = 79) had better OS than the non-radiotherapy group (N = 64) in the first 25 years, and the prognosis in the later years was not significantly different (P = 0.051). The chemotherapy group (N = 37) had a significantly better prognosis than the non-chemotherapy group (N = 37; P = 0.020). Patients who received postoperative radiotherapy (N = 45) or who only received radiotherapy (N = 34) seemed to have better OS than that of patients who only received surgery (N = 33), although the difference was not significant (P = 0.063). CONCLUSIONS: Age and pathological type were independent prognostic factors for thymic lymphoma. Surgical treatment had limited effects on OS, while both radiotherapy and chemotherapy could significantly improve the survival outcome.
format Online
Article
Text
id pubmed-9516097
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95160972022-09-29 Incidence, mortality, and survival analyses of patients with thymic lymphoma Wang, Li Wang, Zhile Huo, Lanqing Zhao, Ailin Front Oncol Oncology OBJECTIVES: To explore the clinical and prognostic characteristics of thymic lymphoma and the effects of current treatments on the prognosis. METHODS: Patients diagnosed as primary thymic lymphoma between 1975 and 2018 from the nine states of the US were identified, including Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle–Puget Sound, and Utah. Incidence and mortality rates were analyzed using SEER*Stat 8.3.9 software. Univariate and multivariate Cox regressions were performed to identify prognostic factors. The Kaplan–Meier curve and log-rank test were used to compare overall survival (OS) among different treatments. RESULTS: A total of 233 patients diagnosed as thymic lymphoma were identified, and eight of them were lost to follow-up or died upon diagnosis. The incidence of thymic lymphoma was 2.032 per ten million (95% CI: 1.777–2.312), and the mortality rate was 0.649 per ten million (95% CI: 0.508–0.817). Among the 225 patients with definite follow-up, 98 were males and 127 were females, with a median age of 33 years. The Cox regression results showed that age and pathological type were independent risk prognostic factors. The 5-, 10-, and 20-year OS were 80.0%, 77.5%, and 70.9%, respectively. For Ann Arbor stage I and II patients, there was no significant difference between the surgical group (N = 78) and the non-operative group (N = 65; P = 0.270). The radiotherapy group (N = 79) had better OS than the non-radiotherapy group (N = 64) in the first 25 years, and the prognosis in the later years was not significantly different (P = 0.051). The chemotherapy group (N = 37) had a significantly better prognosis than the non-chemotherapy group (N = 37; P = 0.020). Patients who received postoperative radiotherapy (N = 45) or who only received radiotherapy (N = 34) seemed to have better OS than that of patients who only received surgery (N = 33), although the difference was not significant (P = 0.063). CONCLUSIONS: Age and pathological type were independent prognostic factors for thymic lymphoma. Surgical treatment had limited effects on OS, while both radiotherapy and chemotherapy could significantly improve the survival outcome. Frontiers Media S.A. 2022-09-14 /pmc/articles/PMC9516097/ /pubmed/36185268 http://dx.doi.org/10.3389/fonc.2022.933672 Text en Copyright © 2022 Wang, Wang, Huo and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Li
Wang, Zhile
Huo, Lanqing
Zhao, Ailin
Incidence, mortality, and survival analyses of patients with thymic lymphoma
title Incidence, mortality, and survival analyses of patients with thymic lymphoma
title_full Incidence, mortality, and survival analyses of patients with thymic lymphoma
title_fullStr Incidence, mortality, and survival analyses of patients with thymic lymphoma
title_full_unstemmed Incidence, mortality, and survival analyses of patients with thymic lymphoma
title_short Incidence, mortality, and survival analyses of patients with thymic lymphoma
title_sort incidence, mortality, and survival analyses of patients with thymic lymphoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516097/
https://www.ncbi.nlm.nih.gov/pubmed/36185268
http://dx.doi.org/10.3389/fonc.2022.933672
work_keys_str_mv AT wangli incidencemortalityandsurvivalanalysesofpatientswiththymiclymphoma
AT wangzhile incidencemortalityandsurvivalanalysesofpatientswiththymiclymphoma
AT huolanqing incidencemortalityandsurvivalanalysesofpatientswiththymiclymphoma
AT zhaoailin incidencemortalityandsurvivalanalysesofpatientswiththymiclymphoma